Advances in the clinical translation of nanotechnology.

Autor: Scheinberg DA; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: scheinbd@mskcc.org., Grimm J; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Heller DA; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Stater EP; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Bradbury M; Radiology Department, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., McDevitt MR; Radiology Department, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Jazyk: angličtina
Zdroj: Current opinion in biotechnology [Curr Opin Biotechnol] 2017 Aug; Vol. 46, pp. 66-73. Date of Electronic Publication: 2017 Feb 07.
DOI: 10.1016/j.copbio.2017.01.002
Abstrakt: The use of novel materials in the nano-scale size range for applications in devices, drugs and diagnostic agents comes with a number of new opportunities, and also serious challenges to human applications. The larger size of particulate-based agents, as compared to traditional drugs, allows for the significant advantages of multivalency and multi-functionality. However, the human use of nanomaterials requires a thorough understanding of the biocompatibility of the synthetic molecules and their complex pharmacology. Possible toxicities created by the unusual properties of the nanoparticles are neither well-understood, nor predictable yet. A key to the successful use of the burgeoning field of nanomaterials as diagnostic and therapeutic agents will be to appropriately match the biophysical features of the particle to the disease system to be evaluated or treated.
(Copyright © 2017 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: